Content
June 2017, Volume 1, Issue 2
- 133-141 Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes
by Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers - 143-143 Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio
March 2017, Volume 1, Issue 1
- 1-12 The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
by Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas - 13-23 Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
by Jeff Richardson & Angelo Iezzi & Gang Chen & Aimee Maxwell - 25-36 Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
by Jameel Nazir & Malin Berling & Charles McCrea & Francis Fatoye & Sally Bowditch & Zalmai Hakimi & Adrian Wagg - 37-51 Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model
by Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer - 53-63 A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy
by Eric C. Leuthardt & Jeff Voigt & Albert H. Kim & Pete Sylvester - 65-68 Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review
by Ilke Akpinar & Philip Jacobs & Tien Dat Tran - 69-70 Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
by Przemysław Holko - 71-71 Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”
by Ilke Akpinar & Philip Jacobs & Dat T. Tran
Printed from https://ideas.repec.org/s/spr/pharmo4.html